Superhigh-magnetization nanocarrier as a doxorubicin delivery platform for magnetic targeting therapy

Mu Yi Hua; Hung Wei Yang; Hao Li Liu; Rung Ywan Tsai; See Tong Pang; Kun Lung Chuang; Yu Sun Chang; Tsong Long Hwang; Ying Hsu Chang; Heng Chang Chuang; Cheng Keng Chuang

doi:10.1016/j.biomaterials.2011.08.014

Superhigh-magnetization nanocarrier as a doxorubicin delivery platform for magnetic targeting therapy

Mu Yi Hua^*, Hung Wei Yang, Hao Li Liu, Rung Ywan Tsai, See Tong Pang, Kun Lung Chuang, Yu Sun Chang, Tsong Long Hwang, Ying Hsu Chang, Heng Chang Chuang, Cheng Keng Chuang

^*Corresponding author for this work

Research output: Contribution to journal › Journal Article › peer-review

79 Scopus citations

Abstract

The aim of this study describes the creation of superhigh-magnetization nanocarriers (SHMNCs) comprised of a magnetic Fe ₃O ₄ (SHMNPs) core and a shell of aqueous stable self-doped poly[N-(1-one-butyric acid)]aniline (SPAnH), which have a high drug loading capacity (∼27.1 wt%) of doxorubicin (DOX). The SHMNCs display superparamagnetic property with a magnetization of 89.7 emu/g greater than that of Resovist (a commercial contrast agent used for magnetic resonance imaging; 73.7 emu/g). Conjugating the anticancer drug DOX to these nanocarriers enhances the drug's thermal stability and maximizes the efficiency with which it is delivered by magnetic targeting (MT) therapy to MGH-U1 bladder cancer cells, in part by avoiding the effects of p-glycoprotein (P-gp) pumps to enhance the intracellular concentration of DOX. The high R2 relaxivity (434.7 mM ^-1s ^-1) of SHMNCs not only be a most effective MT carrier of chemotherapeutic agent but be an excellent contrast agent of MRI, allowing the assessment of the distribution and concentration of DOX in various tissues and organs. This advanced drug delivery system promises to provide more effective MT therapy and tumor treatment using lower therapeutic doses and potentially reducing the side effects of cardiotoxicity caused by DOX.

Original language	English
Pages (from-to)	8999-9010
Number of pages	12
Journal	Biomaterials
Volume	32
Issue number	34
DOIs	https://doi.org/10.1016/j.biomaterials.2011.08.014
State	Published - 12 2011

Keywords

Bladder cancer
Magnetic resonance image
Magnetic targeting therapy
P-glycoprotein pump
Superhigh-magnetization nanocarriers

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.biomaterials.2011.08.014

Cite this

@article{1114c4abf557454e8e1cbc6655ed2611,

title = "Superhigh-magnetization nanocarrier as a doxorubicin delivery platform for magnetic targeting therapy",

abstract = "The aim of this study describes the creation of superhigh-magnetization nanocarriers (SHMNCs) comprised of a magnetic Fe 3O 4 (SHMNPs) core and a shell of aqueous stable self-doped poly[N-(1-one-butyric acid)]aniline (SPAnH), which have a high drug loading capacity (∼27.1 wt%) of doxorubicin (DOX). The SHMNCs display superparamagnetic property with a magnetization of 89.7 emu/g greater than that of Resovist (a commercial contrast agent used for magnetic resonance imaging; 73.7 emu/g). Conjugating the anticancer drug DOX to these nanocarriers enhances the drug's thermal stability and maximizes the efficiency with which it is delivered by magnetic targeting (MT) therapy to MGH-U1 bladder cancer cells, in part by avoiding the effects of p-glycoprotein (P-gp) pumps to enhance the intracellular concentration of DOX. The high R2 relaxivity (434.7 mM -1s -1) of SHMNCs not only be a most effective MT carrier of chemotherapeutic agent but be an excellent contrast agent of MRI, allowing the assessment of the distribution and concentration of DOX in various tissues and organs. This advanced drug delivery system promises to provide more effective MT therapy and tumor treatment using lower therapeutic doses and potentially reducing the side effects of cardiotoxicity caused by DOX.",

keywords = "Bladder cancer, Magnetic resonance image, Magnetic targeting therapy, P-glycoprotein pump, Superhigh-magnetization nanocarriers",

author = "Hua, {Mu Yi} and Yang, {Hung Wei} and Liu, {Hao Li} and Tsai, {Rung Ywan} and Pang, {See Tong} and Chuang, {Kun Lung} and Chang, {Yu Sun} and Hwang, {Tsong Long} and Chang, {Ying Hsu} and Chuang, {Heng Chang} and Chuang, {Cheng Keng}",

year = "2011",

month = dec,

doi = "10.1016/j.biomaterials.2011.08.014",

language = "英语",

volume = "32",

pages = "8999--9010",

journal = "Biomaterials",

issn = "0142-9612",

publisher = "Elsevier Ltd",

number = "34",

}

TY - JOUR

T1 - Superhigh-magnetization nanocarrier as a doxorubicin delivery platform for magnetic targeting therapy

AU - Hua, Mu Yi

AU - Yang, Hung Wei

AU - Liu, Hao Li

AU - Tsai, Rung Ywan

AU - Pang, See Tong

AU - Chuang, Kun Lung

AU - Chang, Yu Sun

AU - Hwang, Tsong Long

AU - Chang, Ying Hsu

AU - Chuang, Heng Chang

AU - Chuang, Cheng Keng

PY - 2011/12

Y1 - 2011/12

N2 - The aim of this study describes the creation of superhigh-magnetization nanocarriers (SHMNCs) comprised of a magnetic Fe 3O 4 (SHMNPs) core and a shell of aqueous stable self-doped poly[N-(1-one-butyric acid)]aniline (SPAnH), which have a high drug loading capacity (∼27.1 wt%) of doxorubicin (DOX). The SHMNCs display superparamagnetic property with a magnetization of 89.7 emu/g greater than that of Resovist (a commercial contrast agent used for magnetic resonance imaging; 73.7 emu/g). Conjugating the anticancer drug DOX to these nanocarriers enhances the drug's thermal stability and maximizes the efficiency with which it is delivered by magnetic targeting (MT) therapy to MGH-U1 bladder cancer cells, in part by avoiding the effects of p-glycoprotein (P-gp) pumps to enhance the intracellular concentration of DOX. The high R2 relaxivity (434.7 mM -1s -1) of SHMNCs not only be a most effective MT carrier of chemotherapeutic agent but be an excellent contrast agent of MRI, allowing the assessment of the distribution and concentration of DOX in various tissues and organs. This advanced drug delivery system promises to provide more effective MT therapy and tumor treatment using lower therapeutic doses and potentially reducing the side effects of cardiotoxicity caused by DOX.

AB - The aim of this study describes the creation of superhigh-magnetization nanocarriers (SHMNCs) comprised of a magnetic Fe 3O 4 (SHMNPs) core and a shell of aqueous stable self-doped poly[N-(1-one-butyric acid)]aniline (SPAnH), which have a high drug loading capacity (∼27.1 wt%) of doxorubicin (DOX). The SHMNCs display superparamagnetic property with a magnetization of 89.7 emu/g greater than that of Resovist (a commercial contrast agent used for magnetic resonance imaging; 73.7 emu/g). Conjugating the anticancer drug DOX to these nanocarriers enhances the drug's thermal stability and maximizes the efficiency with which it is delivered by magnetic targeting (MT) therapy to MGH-U1 bladder cancer cells, in part by avoiding the effects of p-glycoprotein (P-gp) pumps to enhance the intracellular concentration of DOX. The high R2 relaxivity (434.7 mM -1s -1) of SHMNCs not only be a most effective MT carrier of chemotherapeutic agent but be an excellent contrast agent of MRI, allowing the assessment of the distribution and concentration of DOX in various tissues and organs. This advanced drug delivery system promises to provide more effective MT therapy and tumor treatment using lower therapeutic doses and potentially reducing the side effects of cardiotoxicity caused by DOX.

KW - Bladder cancer

KW - Magnetic resonance image

KW - Magnetic targeting therapy

KW - P-glycoprotein pump

KW - Superhigh-magnetization nanocarriers

UR - http://www.scopus.com/inward/record.url?scp=80053127356&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2011.08.014

DO - 10.1016/j.biomaterials.2011.08.014

M3 - 文章

C2 - 21872924

AN - SCOPUS:80053127356

SN - 0142-9612

VL - 32

SP - 8999

EP - 9010

JO - Biomaterials

JF - Biomaterials

IS - 34

ER -

Superhigh-magnetization nanocarrier as a doxorubicin delivery platform for magnetic targeting therapy

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this